Every 8-K that Polaryx Therapeutics, Inc. (PLYX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PLYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLYX filings page.
Polaryx Therapeutics, Inc. (PLYX) reported the results of its September 10, 2026 Annual Meeting of Stockholders. Stockholders elected Class I directors Alex Yang and Mitchel Berger to serve until the 2029 annual meeting, or until their successors are elected and qualified. Each director received 30,072,137 votes cast for, 332 votes withheld, and 472,610 broker non-votes. Stockholders also ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 30,510,106 votes for, 34,973 against, and no abstentions and no broker non-votes for this proposal.
Polaryx Therapeutics, Inc. (PLYX) reported the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of rare disease and pediatric drug development experience, including senior roles at Tyra Biosciences, Spruce Biosciences, 89bio, Ascendis Pharma, and Allergan.
The company highlighted his role in leading Phase 2 rare disease programs and redesigning clinical strategies for pediatric indications. Polaryx reiterated plans to initiate SOTERIA, a Phase 2 open-label, single-arm trial of PLX-200 in multiple lysosomal storage disorders, in the fourth quarter of 2026, initially at sites in the United States and then other jurisdictions.
Polaryx Therapeutics, Inc. reported that its Chief Medical Officer, Lisa Bollinger, MD, resigned from her position effective immediately on July 19, 2026. The company states it does not anticipate this departure will affect its previously disclosed clinical timelines, regulatory plans or development strategy. A search for a successor has begun, and in the meantime, existing members of the leadership team will assume the responsibilities previously overseen by Dr. Bollinger.
Polaryx Therapeutics, Inc. determined that its 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026. Stockholders of record of the company’s common stock at the close of business on July 27, 2026 will be entitled to notice of and to vote at the meeting, subject to the company’s reserved right to change the record date, meeting date, or location.
Because no annual meeting was held in 2025, stockholder proposals and director nominations intended for inclusion in the proxy materials under Rule 14a-8 must be received by the company, attention Alex Yang at its Paramus, New Jersey address, by the close of business on July 27, 2026 and must comply with SEC rules, Nevada law and the company’s Amended and Restated Bylaws. Proposals or nominations received after that date will be considered untimely and will not be included or considered at the meeting.
Polaryx Therapeutics, Inc. entered into a private placement, selling 2,502,696 common shares for aggregate gross proceeds of $10 million, representing about 5.3% of its outstanding shares immediately before the transaction. The weighted average price was approximately $4.00 per share.
The company plans to use the net proceeds, together with existing cash, to fund its Phase 2 SOTERIA basket trial of PLX-200 across multiple lysosomal storage disorders, continue research and development, and for working capital and general corporate purposes. Management states this financing is expected to extend Polaryx’s operating runway through the second quarter of 2027 and support the planned launch of SOTERIA in the second half of 2026.